You are on Facebook, right?

It’s not the end of the world if you’re not – but you are just missing out on the opportunity to connect with more people who are passionate about lymphoma and leukemia. In case you’ve been living in a cave for the past two years, let me fill you in. Facebook is a social media site, where you create a profile, and can reconnect with old friends, family members and meet new people.

Once you are a member of Facebook, you just type the subject that interests you in the search engine box and a list of groups and organizations will pop up. The main difference between Facebook and a website is that Facebook is much more interactive.

For example, the Leukemia and Lymphoma group has over 26,000 members on Facebook. The group’s page includes polls, videos, up to the minute research announcements, education seminar information, discussions and more. It is an easy way to make connections with people around the world.

Warning: Facebook can be a huge time suck if you’re not careful, so make sure to plan just how much time you want to spend online sending virtual gifts, playing games like Bejeweled Blitz (my personal weakness), or creating virtual farms, aquariums, restaurants, and mafia wars. Come beat me at Bejeweled, I dare you!

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap